Skip to main content
OpenTrials

Clinical trial condition

Renal Cell Carcinoma

Explore clinical trials studying Renal Cell Carcinoma. Study availability and eligibility vary by location and protocol.

412 public trials 75 recruiting studies
Refine in advanced search Browse all conditions

Renal Cell Carcinoma trial results

Completed

Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)

NCT03063762

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Yale Cancer Center; Medical Oncology New Haven, Connecticut, United States
  • Northwestern Center for Clinical Research; Cancer Center Chicago, Illinois, United States
  • University of Maryland Greenebaum Comprehensive Cancer Center Baltimore, Maryland, United States
  • Princess Margaret Cancer Center Toronto, Ontario, Canada
View all 23 locations
View Trial Details
Completed

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

NCT02420821

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • University of California at Irvine Medical Center; Department of Oncology Orange, California, United States
  • University of California San Francisco, California, United States
  • University of Colorado; Anschutz Cancer Pavilion Aurora, Colorado, United States
View all 154 locations
View Trial Details
Completed

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

NCT03517488

Conditions
Adenocarcinoma, Adenoma, Adnexal Diseases, +129 more
Locations
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute Los Angeles, California, United States
  • UCLA Hematology-Oncology Clinic (Westwood) Los Angeles, California, United States
  • University of California San Diego Moores Cancer Center San Diego, California, United States
  • University of California San Francisco Medical Center San Francisco, California, United States
View all 17 locations
View Trial Details
Completed

A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer

NCT02982954

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Northwest Alabama Cancer Center, Pc Muscle Shoals, Alabama, United States
  • Alaska Urological Institute dba Alaska Clinical Research Center Anchorage, Alaska, United States
  • Ironwood Cancer And Research Centers, Pc Chandler, Arizona, United States
  • Local Institution - 0028 Fayetteville, Arkansas, United States
View all 61 locations
View Trial Details
Completed

An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma

NCT02596035

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Local Institution - 0030 Phoenix, Arizona, United States
  • Comprehensive Blood And Cancer Center Bakersfield, California, United States
  • St. Jude Hospital Yorba Linda Fullerton, California, United States
  • Cancer Care Associates Medical Group, Inc. Redondo Beach, California, United States
View all 39 locations
View Trial Details
Completed

Spanish Real-World Evidence Cabozantinib

NCT04510688

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Hospital Universitario Reina Sofía Córdoba, Andalusia, Spain
  • Hospital Universitario Juan Ramón Jiménez Huelva, Andalusia, Spain
  • Complejo Hospitalario de Jaén Jaén, Andalusia, Spain
  • Hospital Son Llatzer Palma de Mallorca, Balearic Islands, Spain
View all 32 locations
View Trial Details
Completed

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

NCT01975831

Conditions
Adenocarcinoma, Adnexal Diseases, Breast Cancer, +44 more
Locations
  • Yale Cancer Center New Haven, Connecticut, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details

Related conditions